These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 28587944)

  • 21. Prevalence of hepatitis C virus in young people who inject drugs in four Colombian cities: A cross-sectional study using Respondent Driven Sampling.
    Toro-Tobón D; Berbesi-Fernandez D; Mateu-Gelabert P; Segura-Cardona ÁM; Montoya-Vélez LP
    Int J Drug Policy; 2018 Oct; 60():56-64. PubMed ID: 30107313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
    Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs.
    Stephens DB; Young AM; Havens JR
    Int J Drug Policy; 2017 Sep; 47():86-94. PubMed ID: 28648353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug use-related stigma, safer injection norms, and hepatitis C infection among a network-based sample of young people who inject drugs.
    Williams LD; Mackesy-Amiti ME; Latkin C; Boodram B
    Drug Alcohol Depend; 2021 Apr; 221():108626. PubMed ID: 33689967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
    J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus prevalence, determinants, and cascade of care among people who inject drugs in Iran.
    Khezri M; Mirzazadeh A; Shokoohi M; Sharafi H; Ghalekhani N; Tavakoli F; Mehmandoost S; Mousavian G; Imani M; Kakavand-Ghalehnoei R; Komasi A; Gouya MM; Haghdoost AA; McFarland W; Karamouzian M; Sharifi H
    Drug Alcohol Depend; 2023 Feb; 243():109751. PubMed ID: 36621200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada.
    Fortier E; Artenie AA; Zang G; Jutras-Aswad D; Roy É; Grebely J; Bruneau J
    Addiction; 2019 Aug; 114(8):1495-1503. PubMed ID: 30957310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recommendations for the management of hepatitis C virus infection among people who inject drugs.
    Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S129-37. PubMed ID: 23884061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study.
    Roux P; Rojas Castro D; Ndiaye K; Debrus M; Protopopescu C; Le Gall JM; Haas A; Mora M; Spire B; Suzan-Monti M; Carrieri P
    PLoS One; 2016; 11(6):e0157062. PubMed ID: 27294271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.
    Braitstein P; Li K; Kerr T; Montaner JS; Hogg RS; Wood E
    AIDS Care; 2006 Oct; 18(7):690-3. PubMed ID: 16971276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era.
    Falade-Nwulia O; Gicquelais RE; Astemborski J; McCormick SD; Kirk G; Sulkowski M; Thomas DL; Mehta SH
    Liver Int; 2020 Oct; 40(10):2407-2416. PubMed ID: 32770638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
    Jacka B; Roy É; Høj S; Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Bruneau J
    J Viral Hepat; 2019 Dec; 26(12):1413-1422. PubMed ID: 31433888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review.
    Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J
    Int J Drug Policy; 2017 Sep; 47():34-46. PubMed ID: 28797498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention.
    Eckhardt B; Winkelstein ER; Shu MA; Carden MR; McKnight C; Des Jarlais DC; Glesby MJ; Marks K; Edlin BR
    PLoS One; 2017; 12(5):e0177341. PubMed ID: 28542351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network.
    Morris L; Smirnov A; Kvassay A; Leslie E; Kavanagh R; Alexander N; Davey G; Williams O; Gilks C; Najman J
    Int J Drug Policy; 2017 Sep; 47():216-220. PubMed ID: 28666635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
    Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
    Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
    Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
    J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs.
    Doyle M; Maher L; Graham S; Wand H; Iversen J
    Aust N Z J Public Health; 2018 Feb; 42(1):52-56. PubMed ID: 29168317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
    Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
    J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs.
    Prouté M; Le Coeur S; Tiv MH; Dub T; Jongpaijitsakul P; Ratnamhin A; Angkurawaranon C; Aramrattana A; Lallemant M
    BMC Public Health; 2020 Sep; 20(1):1450. PubMed ID: 32972359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.